Literature DB >> 7875194

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection.

F Lehmann1, M Marchand, P Hainaut, P Pouillart, X Sastre, H Ikeda, T Boon, P G Coulie.   

Abstract

We have studied the patterns of antigens recognized by autologous cytolytic T lymphocytes (CTL) on two melanoma cell lines derived from metastases that were removed from patient LB33 at several years distance. Cell line LB33-MEL.A was obtained after surgery in 1988. A large number of CTL clones directed against LB33-MEL.A was obtained with blood lymphocytes collected from the patient in 1990. In vitro selection of melanoma cells that were resistant to these CTL clones indicated that at least five different antigens were recognized on LB33-MEL.A by autologous CTL. Four of these antigens were found to be presented by HLA-A28, B13, B44 and Cw6, respectively. The patient remained disease-free until 1993 when a metastasis was detected and was used to obtain cell line LB33-MEL.B. This cell line proved resistant to lysis by all the CTL clones directed against the LB33-MEL.A cells and showed no expression of HLA class I molecules except for HLA-A24. Using LB33-MEL.B cells to stimulate blood lymphocytes collected from the patient in 1994 we derived CTL clones that lysed these cells. All these CTL clones recognized a new antigen presented by HLA-A24. These results suggest that in patient LB33 the melanoma cells may have lost the expression of several HLA molecules under the selective pressure of an anti-tumor CTL response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875194     DOI: 10.1002/eji.1830250206

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

Review 1.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

2.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

3.  Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.

Authors:  M Wang; P W Chen; V Bronte; S A Rosenberg; N P Restifo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-10

4.  Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model.

Authors:  Y Ichinose; T Okino; S Yamasaki; Y Moriguchi; T Sugie; L Li; S Kanaoka; N Kan; Y Watanabe; M Imamura
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

5.  Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.

Authors:  A Porgador; O Mandelboim; N P Restifo; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.

Authors:  M W Carroll; W W Overwijk; R S Chamberlain; S A Rosenberg; B Moss; N P Restifo
Journal:  Vaccine       Date:  1997-03       Impact factor: 3.641

7.  HeLa cells cocultured with peripheral blood lymphocytes acquire an immuno-inhibitory phenotype through up-regulation of indoleamine 2,3-dioxygenase activity.

Authors:  Grant J Logan; Christine M F Smyth; John W Earl; Irina Zaikina; Peter B Rowe; Jason A Smythe; Ian E Alexander
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

8.  Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy.

Authors:  Chien-Chung Chang; Giuseppe Pirozzi; Shao-Hsuan Wen; I-Hsin Chung; Bau-Lin Chiu; Simona Errico; Monica Luongo; Maria Luisa Lombardi; Soldano Ferrone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

9.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.

Authors:  M J Maeurer; S M Gollin; D Martin; W Swaney; J Bryant; C Castelli; P Robbins; G Parmiani; W J Storkus; M T Lotze
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

10.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.